Amphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
April 06 2021 - 4:05PM
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that
Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and
HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations,
and Jacob Liawatidewi, Executive V.P. Corporate Administration
Center and Sales & Marketing, will participate in an
Analyst-Moderated fireside chat at the Needham Virtual Healthcare
Conference on Tuesday, April 13, 2021 at 3:45 pm Eastern time.
This presentation will be made available webcast
and may be accessed by visiting Amphastar’s Pharmaceuticals website
at http://ir.amphastar.com. This webcast will be available for 90
days following the presentation.
About Amphastar:
Amphastar is a specialty pharmaceutical company
that focuses primarily on developing, manufacturing, marketing, and
selling technically-challenging generic and proprietary injectable,
inhalation, and intranasal products. Additionally, the Company
sells insulin active pharmaceutical ingredient products. Most of
the Company’s finished products are used in hospital or urgent care
clinical settings and are primarily contracted and distributed
through group purchasing organizations and drug wholesalers. More
information is available at the Company’s website at
www.amphastar.com.
The Amphastar Pharmaceuticals’ logo and other
trademarks or service marks of Amphastar
Pharmaceuticals, Inc., including, but not limited to
Primatene®, Amphadase® and Cortrosyn®, are the property of
Amphastar Pharmaceuticals, Inc.
Forward Looking Statements
All statements in this press release that are not
historical are forward-looking statements. These statements are not
historical facts but rather are based on Amphastar’s historical
performance and its current expectations, estimates, and
projections regarding Amphastar’s business, operations, and other
similar or related factors. Words such as “may,” “might,” “will,”
“could,” “would,” “should,” “anticipate,” “predict,” “potential,”
“continue,” “expect,” “intend,” “plan,” “project,” “believe,”
“estimate,” and other similar or related expressions are used to
identify these forward-looking statements, although not all
forward-looking statements contain these words. You should not
place undue reliance on forward-looking statements because they
involve known and unknown risks, uncertainties, and assumptions
that are difficult or impossible to predict and, in some cases,
beyond Amphastar’s control. Actual results may differ materially
from those in the forward-looking statements as a result of a
number of factors, including those described in Amphastar’s filings
with the Securities and Exchange Commission, including in the
Annual Report on Form 10-K for the year ended December 31, 2020,
filed with the SEC on March 15, 2021. You can locate these reports
through the Company’s website at http://ir.amphastar.com and on the
SEC’s website at www.sec.gov. The forward-looking statements in
this release speak only as of the date of the release. Amphastar
undertakes no obligation to revise or update information or any
forward-looking statements in this press release to reflect events
or circumstances in the future, even if new information becomes
available or if subsequent events cause Amphastar’s expectations to
change.
Contact: |
|
Bill Peters Chief Financial Officer (909) 476-3416 |
|
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amphastar Pharmaceuticals (NASDAQ:AMPH)
Historical Stock Chart
From Apr 2023 to Apr 2024